OPT.AU · Opthea Limited

-

Please sign in to comment on OPT.AU

1 Comment

Admin

4 years, 8 months ago

Opthea Limited is currently in a long term downtrend where the price is trading 27.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Opthea Limited's total revenue rose by 15.1% to $314K since the same quarter in the previous year.

Its net income has dropped by 359.1% to $-35M since the same quarter in the previous year.

Finally, its free cash flow fell by 733.9% to $-12M since the same quarter in the previous year.

Based on the above factors, Opthea Limited gets an overall score of 2/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000OPT2
Sector	Healthcare
Industry	Biotechnology

Market Cap	821M
PE Ratio	None
Target Price	1.5
Beta	1.67
Dividend Yield	None

ABOUT

Opthea Limited

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

OPT.AU · Opthea Limited

-

Opthea Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Opthea Limited using a moving average strategy